Navigation Links
Transgenomic to Hold First Quarter Financial Results Conference Call on May 12, 2011
Date:5/5/2011

OMAHA, Neb., May 5, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) today announced the following Webcast:What:

Transgenomic, Inc. First Quarter 2011 Financial Results and Business Update Conference CallWhen:

Thursday, May 12, 2011 @ 5:00 p.m. EasternWhere:

http://www.transgenomic.com/events.asp?id=6How:

Live over the Internet -- Simply log on to the web at the address above.Contact:

Investor Relations, 402-452-5400To access the call via telephone, call 800-895-0198 from the U.S. or Canada or 785-424-1053 for international participants and enter conference ID TRANS.  A telephone replay will be available from 6:00 p.m. Eastern Time May 12, 2011 through 11:59 p.m. Eastern Time on May 26, 2011 by dialing 800-374-0328 (domestic) or 402-220-0663 (international).

About Transgenomic, Inc.Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Product offerings include the WAVE Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,500 systems have been installed in customers' labs in more than 50 countries. The SURVEYOR Mutation Detection Kits provide reagents and protocols for high sensitivity detection of mutations in DNA. HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic karyotyping and FISH analyses. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials. The Transgenomic Molecular Laboratories specialize in molecular diagnostics for cardiology, neurology, mitochondrial disorders, oncology, hematology, molecular pathology and other inherited diseases. Transgenomic believes there is a significant opportunity to continue growing the demand for its molecular-based testing by leveraging core technologies, experience, and expertise in biomarker analysis. In addition, the company continues to seek out and evaluate new technologies and new tests to extend its offerings in molecular diagnostics and pharmacogenomics services.


'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic, Inc. Enhances FAMILION® Genetic Test Offerings
2. Transgenomic, Inc. Presentations to Describe High-Sensitivity Detection of Cancer Biomarkers at the 2011 American Association for Cancer Research Meeting
3. Transgenomic Announces Discovery of a Novel Technique Which Enhances Analytic Sensitivity of Standard Sanger Sequencing to 1%
4. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
5. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
6. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
7. Transgenomic Reports Third Quarter Financial Results
8. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
9. Transgenomic to Hold Third Quarter Financial Results Conference Call on November 15, 2010
10. Transgenomic Develops New Assays to Detect EGFR Mutations Using COLD-PCR
11. Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 18, 2017 , ... The ... (NIH) to update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, ... subject to the existing policy. AMIA recommended that NIH earmark funding for researchers ...
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017   Boston ... novel compounds designed to target cancer stemness pathways, will ... investigational compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers ... Francisco . Napabucasin is an ... by targeting STAT3. i Cancer stem cells (CSCs) ...
(Date:1/18/2017)... ... January 18, 2017 , ... Whitehouse Labs has furthered ... Molecular Research, Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & ... further growth in 2017. Extractable & Leachable evaluations have become increasingly more vital ...
Breaking Biology Technology:
(Date:1/11/2017)... 2017  Michael Johnson, co-founder of Visikol Inc. a company originally ... been named to the elite "Forbes 30 Under 30" list in ... people in 20 fields nationwide to be recognized as a leader ... were selected. ... is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... Jan. 4, 2017  For the thousands of attendees at this year,s ... in connected health and biometric measurement devices and services, will be featuring ... On display in A&D Medical,s special CES Exhibit Suite , the ... expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
Breaking Biology News(10 mins):